Completed PHASE2 INTERVENTIONAL 4-arm NCT00619476

A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)

Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN)

Sponsor: XenoPort, Inc.

Conditions Neuralgia, Postherpetic

Interventions GEn 1200mg/day GEn 2400mg/day GEn 3600mg/day Placebo

Updated 7 times since 2017 Last updated: Jul 15, 2013 Started: Feb 29, 2008 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Neuralgia, Postherpetic and is currently completed. XenoPort, Inc. leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

XenoPort, Inc.

Data source: XenoPort, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Altoona, United States , Amherst, United States , Arcadia, United States , Bingham Farms, United States , Birmingham, United States , Boston, United States , Boulder, United States , Bradenton, United States , Brampton, Canada and 69 more locations